{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:05:03Z","timestamp":1790449503953,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"SMA Europe and Daniel Bravo Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.nmd.2017.05.011","type":"journal-article","created":{"date-parts":[[2017,5,16]],"date-time":"2017-05-16T22:45:42Z","timestamp":1494974742000},"page":"883-889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"title":["Spinal muscular atrophy: A changing phenotype beyond the clinical trials"],"prefix":"10.1016","volume":"27","author":[{"given":"Eduardo F.","family":"Tizzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2017.05.011_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.nmd.2008.10.004","article-title":"Ramblings in the history of spinal muscular atrophy","volume":"19","author":"Dubowitz","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2017.05.011_bib0015","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","article-title":"International SMA consortium meeting (26\u201328 June 1992, Bonn, Germany)","volume":"2","author":"Munsat","year":"1992","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2017.05.011_bib0020","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000052118","article-title":"The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III","volume":"45","author":"Rudnik-Sch\u00f6neborn","year":"2001","journal-title":"Eur Neurol"},{"key":"10.1016\/j.nmd.2017.05.011_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0960-8966(94)00075-K","article-title":"Chaos in the classification of SMA: a possible resolution","volume":"5","author":"Dubowitz","year":"1995","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2017.05.011_bib0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.nmd.2017.05.011_bib0035","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","article-title":"An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)","volume":"15","author":"Wirth","year":"2000","journal-title":"Hum Mutat"},{"key":"10.1016\/j.nmd.2017.05.011_bib0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00439-008-0598-1","article-title":"Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene","volume":"125","author":"Al\u00edas","year":"2009","journal-title":"Hum Genet"},{"key":"10.1016\/j.nmd.2017.05.011_bib0045","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2017.05.011_bib0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00415-005-0912-y","article-title":"SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings","volume":"253","author":"Cusc\u00f3","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2017.05.011_bib0055","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.bbadis.2014.07.024","article-title":"Molecular mechanisms and animal models of spinal muscular atrophy","volume":"1852","author":"Edens","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.nmd.2017.05.011_bib0060","first-page":"21","article-title":"Developmental aspects and pathological findings in spinal muscular atrophy","author":"Perez Garcia","year":"2017","journal-title":"Dis Mech Ther"},{"key":"10.1016\/j.nmd.2017.05.011_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","author":"Crawford","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2017.05.011_bib0070","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","article-title":"Diverse role of survival motor neuron protein","volume":"1860","author":"Singh","year":"2017","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.nmd.2017.05.011_bib0075","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ppul.23616","article-title":"Physician driven variation in the care of children with spinal muscular atrophy type 1","volume":"52","author":"Oskoui","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.nmd.2017.05.011_bib0080","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.nmd.2016.10.002","article-title":"Developmental milestones in type I spinal muscular atrophy","volume":"26","author":"De Sanctis","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2017.05.011_bib0085","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2017.05.011_bib0090","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.nmd.2017.02.014","article-title":"ENMC SMA Workshop Study Group. Revisiting the consensus on standards of care in SMA. Naarden, The Netherlands 19\u201321 February 2016","volume":"27","author":"Finkel","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2017.05.011_bib9010","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ppul.21617","article-title":"International survey of physician recommendation for tracheostomy for spinal muscular atrophy Type I","volume":"47","author":"Benson","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.nmd.2017.05.011_bib0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.arcped.2014.01.017","article-title":"Multicentric study of medical care and practices in spinal muscular atrophy type 1 over two 10-year periods","volume":"21","author":"Barn\u00e9rias","year":"2014","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.nmd.2017.05.011_bib0100","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/adc.2009.166512","article-title":"Implementation of \u201cthe consensus statement for the standard of care in spinal muscular atrophy\u201d when applied to infants with severe type 1 SMA in the UK","volume":"95","author":"Roper","year":"2010","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.nmd.2017.05.011_bib0105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.nmd.2017.05.011_bib0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1083\/jcb.201207087","article-title":"Antisense-based therapy for the treatment of spinal muscular atrophy","volume":"199","author":"Rigo","year":"2012","journal-title":"J Cell Biol"},{"key":"10.1016\/j.nmd.2017.05.011_bib0115","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.nmd.2017.05.011_bib9015","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/S0140-6736(16)32390-X","article-title":"Comment: dawn of a new therapeutic era for spinal muscular atrophy","volume":"388","author":"Gillingwater","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2017.05.011_bib0120","first-page":"2","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"6736","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2017.05.011_bib0125","series-title":"Primary efficacy and safety results from the phase 3 ENDEAR study of nusinersen in infants diagnosed with spinal muscular atrophy (SMA)","author":"Finkel","year":"2017"},{"key":"10.1016\/j.nmd.2017.05.011_bib0130","series-title":"efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA)","author":"Mercuri","year":"2017"},{"key":"10.1016\/j.nmd.2017.05.011_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(17)30085-6","article-title":"Olesoxime SMA Phase 2 Study Investigators. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial","author":"Bertini","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2017.05.011_bib0140","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1007\/s00415-014-7520-7","article-title":"Inherited disorders of the neuromuscular junction: an update","volume":"261","author":"Rodr\u00edguez Cruz","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2017.05.011_bib0145","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/jpet.114.222224","article-title":"The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure","volume":"353","author":"Hwee","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nmd.2017.05.011_bib0150","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2017.05.011_bib0155","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.neuron.2010.12.032","article-title":"Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy","volume":"69","author":"Mentis","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.nmd.2017.05.011_bib0160","first-page":"4109","article-title":"Spinal muscular atrophy: why do low levels of SMN make motor neurons sick?","volume":"22","author":"Burghes","year":"2008","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.nmd.2017.05.011_bib0165","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s13311-015-0337-y","article-title":"Spinal muscular atrophy therapeutics: where do we stand?","volume":"12","author":"D'Ydewalle","year":"2015","journal-title":"Neurother"},{"key":"10.1016\/j.nmd.2017.05.011_bib0170","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","article-title":"Spinal muscular atrophy: going beyond the motor neuron","volume":"19","author":"Hamilton","year":"2013","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.nmd.2017.05.011_bib0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajmg.c.31321","article-title":"Infantile Pompe disease on ERT: update of clinical presentation, musculoskeletal management, and exercise considerations","volume":"160c","author":"Case","year":"2012","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.nmd.2017.05.011_bib0180","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","article-title":"The emerging phenotype of late-onset Pompe disease: a systematic literature review","volume":"120","author":"Chan","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2017.05.011_bib0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/NEN.0000000000000144","article-title":"Spectrum of neuropathophysiology in spinal muscular atrophy type I","volume":"74","author":"Harding","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.nmd.2017.05.011_bib0190","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0960-8966(01)00274-7","article-title":"Intelligence and cognitive function in children and adolescents with spinal muscular atrophy","volume":"12","author":"von Gontard","year":"2002","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2017.05.011_bib0195","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","article-title":"Prospective cohort study of spinal muscular atrophy types 2 and 3","volume":"79","author":"Kaufmann","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2017.05.011_bib0200","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2017.05.011_bib0205","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","article-title":"Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications","volume":"52","author":"Zerres","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2017.05.011_bib0210","doi-asserted-by":"crossref","first-page":"14454","DOI":"10.1038\/ncomms14454","article-title":"Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy","volume":"8","author":"Bengtsson","year":"2017","journal-title":"Nat Commun"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896617301542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896617301542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:05:48Z","timestamp":1760774748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896617301542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0960896617301542"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2017.05.011","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spinal muscular atrophy: A changing phenotype beyond the clinical trials","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2017.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}